Next Generation Drug Conjugates Market

研究執行與發布：Roots Analysis　·　發布日期 2026-08-17　·　266 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

出版商 Roots Analysis 產業別 Healthcare & Life Sciences出版日期 2026-08-17頁數 266報告編號 RA100455

授權報價

Single User	$4,799 USD
Multi User	$7,999 USD
Enterprise / Global Site Licence	$17,999 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Next Generation Drug Conjugates Market (2nd Edition) by Type of Drug Conjugate, Type of Targeting Ligand, Type of Payload, Route of Administration, Type of Therapy, Therapeutic Area, Geographical Regions, and Sales Forecast – Trends and Forecast, Till 2035

報告摘要

NEXT GENERATION DRUG CONJUGATES MARKET: OVERVIEW As per Roots Analysis, the global next generation drug conjugates market is estimated to grow from USD 11.2 billion in the current year to USD 26.2 billion by 2035, at a CAGR of 9.9% during the forecast period, till 2035. NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS Next generation drug conjugates (XDCs) leverage diverse payloads, linker technologies, and targeting mechanisms to facilitate the precise delivery of therapeutic agents to diseased tissues while minimizing off-target toxicity. The incorporation of advanced chemical engineering techniques, innovative design approaches, and highly specific targeting modalities has significantly improved their therapeutic index and efficacy, enabling the development of more sophisticated, site-directed treatment options. The next generation drug conjugates landscape is witnessing rapid expansion, supported by continuous advancements in payload technologies, including oligonucleotides, peptides, and small molecules, as well as innovations in linker design and conjugation platforms that enhance molecular stability and enable controlled drug release. However, despite these technological developments, challenges related to payload-target compatibility, manufacturing scalability, and physicochemical complexity continue to pose barriers to broader adoption and commercialization. Growing application of XDCs across oncology, rare diseases, and immune-mediated disorders, coupled with increasing investments in precision medicine and multimodal therapeutic approaches, is expected to sustain market momentum. As a result, next generation drug conjugates are emerging as a highly promising and transformative segment within the broader conjugate therapeutics industry. Growth Drivers: Strategic Enablers of Market Expansion The next generation drug conjugates (XDCs) field is undergoing rapid evolution, driven by continuous advancements in targeting precision, payload innovation, and hybrid therapeutic design. Improvements in linker stability, payload potency, and targeted delivery technologies are enhancing the therapeutic index of XDCs, enabling more effective eradication of diseased cells while reducing off-target toxicity. At the same time, increasing interest in RNA-based therapeutics is accelerating innovation in oligonucleotide payloads, with developers focusing on improving molecular stability, intracellular delivery, and controlled-release capabilities to unlock new opportunities in precision gene regulation. Building on these advances, the emergence of hybrid XDCs that integrate multiple payload modalities, including small molecules, peptides, and oligonucleotides, is expanding the therapeutic potential of conjugate platforms. These next generation constructs can simultaneously address multiple disease pathways through dual- or multi-mechanism approaches, positioning XDCs as a transformative therapeutic class capable of overcoming the limitations of conventional monotherapies and addressing increasingly complex disease indications. Market Challenges: Critical Barriers Impeding Progress The next generation drug conjugates (XDCs) market continues to face several development and commercialization challenges despite ongoing technological advancements. A key obstacle is achieving optimal compatibility between payloads, linkers, and targeting moieties, as variations in biological targets and intracellular delivery pathways can impact therapeutic efficacy and safety. In addition, the increasing structural complexity of XDCs, particularly those incorporating novel payloads such as oligonucleotides, peptides, and multi-functional constructs, creates significant manufacturing and scalability challenges related to process consistency, quality control, and cost efficiency. Furthermore, the physicochemical complexity of these therapeutics can affect stability, formulation, and pharmacokinetic performance, while evolving regulatory requirements for emerging conjugate modalities often necessitate extensive characterization and validation efforts. Collectively, these factors can prolong development timelines, increase commercialization costs, and present barriers to the broader adoption of next generation drug conjugates. NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS The report delves into the current state of the next generation drug conjugates market and identifies potential growth opportunities within the industry. Some key findings from the report include: 1. More than 320 XDCs (~270 unique therapies) are currently approved / being investigated across various stages of development for various indications; of these, close to 60% are under different phases of clinical trials. 2. Most (40%) of the XDC therapy programs are classified as ligand-drug conjugates; of these, over 95% function through sequence-specific target binding, ensuring covalent stability and exclusive payload delivery to target cells. 3 Most of the trials (~30%) were registered in H2 2025; notably, more than 70% of the registered trials are currently recruiting potential candidates for investigating next generation drug conjugates for various indications. 4. The growing interest in this industry is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to next generation drug conjugates were inked in 2021 and 2024. 5. Close to 70% of the grants related to next generation drug conjugates were allocated for non-small business innovative research / small business technology transfer research. 6. The rising number of scientific articles being published in next generation drug conjugates market is indicative of the substantial efforts being undertaken by various stakeholders active in this domain. 7. 60% of the next generation drug conjugates were discontinued in Phase II of clinical trials; further, more than 45% of the conjugates that have been discontinued till date were ligand mediated RNAi conjugates. 8. The next generation drug conjugates market is likely to grow at an annualized rate (CAGR) of 9.9%, till 2035; notably, the ligand-mediated RNAi conjugates is anticipated to capture the majority share in the market by 2035. 9. Currently, majority of the market share is captured by the genetic disorders sub-segment; a substantial market share is expected to be captured by North America, by 2035. Next Generation Drug Conjugates Market Segments The market sizing and opportunity analysis has been segmented across the following parameters: By Type of Drug Conjugate • Ligand Mediated RNAi Conjugates • Ligand Conjugated Antisense Medicines • Peptide-Radionuclide Conjugates • Small Molecule Drug Conjugates • Virus-like Drug Conjugates • Radioconjugates By Type of Targeting Ligand • Amino Sugars • Peptides • Lipids • Virus-like Particles • Others By Type of Payload • siRNAs • Radionuclides • Antisense Oligonucleotides • Drugs • Others By Route of Administration • Subcutaneous • Intravenous • Suprachoroidal • Others By Type of Therapy • Monotherapies • Combination Therapies • Others By Therapeutic Area • Genetic Disorders • Oncological Disorders • Metabolic Disorders • Cardiovascular Disorders • Autoimmune Disorders • Hematological Disorders • Renal Disorders • Hepatic Disorders By Geographical Regions • North America • US • Canada • Europe • Germany • Spain • France • UK • Italy • Rest of Europe • Asia-Pacific • China • Japan • Australia • Rest of Asia-Pacific • Rest of the World • Brazil • Argentina • Saudi Arabia NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENT INSIGHTS Ligand-Mediated RNAi Conjugates Driving Cancer Therapy Development According to the next generation drug conjugates market forecast, ligand-mediated RNAi conjugates currently dominate the market with approximately 55% share, driven by increasing demand for therapies with enhanced efficacy and improved safety profiles. Growth Potential of Virus-Like Drug Conjugates Virus-like drug conjugates are projected to expand at a higher CAGR, indicating significant growth potential over the forecast period. This growth is attributed to their ability to mimic natural viral entry pathways, enabling highly efficient intracellular delivery of therapeutic payloads. Subcutaneous Administration Driving Market Expansion Based on market forecasts, subcutaneous administration accounts for more than 60% of current revenues across routes of administration. This dominance is supported by ease of administration, improved patient adherence, reduced reliance on hospital-based procedures, rising cancer prevalence, advancements in oncology precision medicine, and increasing R&D investments in the field. Next Generation Drug Conjugate Monotherapies to Remain Dominant According to market analysis, approximately 95% of next generation drug conjugates are currently prescribed as monotherapy, a trend expected to persist in the foreseeable future. This is primarily due to simplified dosing regimens, reduced toxicity, and suitability for long-term disease management and personalized treatment approaches. Recent approvals supporting this trend include GIVLAARI® (givosiran), OXLUMO® (lumasiran), Leqvio® (inclisiran), AMVUTTRA® (vutrisiran), PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), and Illuccix® (Ga-68 PSMA-11). North America Dominating the Market Landscape North America is expected to lead the next generation drug conjugates market, accounting for over 55% share by 2035. This dominance is driven by strong academia–industry collaborations, advanced manufacturing capabilities for complex conjugates, and a robust intellectual property framework. Notable approved XDCs in the region include GIVLAARI®, DAWNZERA™, TRYNGOLZA®, WAINZUA, and Lutathera, which generated approximately USD 0.8 billion in net sales in 2025. Strong Growth Outlook for Europe The European next generation drug conjugates market is projected to grow at a CAGR of approximately 14% over the forecast period. This growth is supported by the presence of leading biopharmaceutical companies such as Novartis, Novo Nordisk, AstraZeneca, and Bayer, which continue to strengthen innovation and development within the region. Example Players in Next Generation Drug Conjugates Market • Alnylam Pharmaceuticals • Arrowhead Pharmaceuticals • Geron • Ionis Pharmaceuticals • Novartis • Novo Nordisk • Stemline Therapeutics • Telix Pharmaceuticals Next Generation Drug Conjugates Market Experts The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of the following third-party discussions: • Doctor of Medicine, Large Organization, Canada, North America • Doctor of Medicine, PhD, Large Organization, Spain, Europe • Vice President of Biologics Engineering and Tumor-Targeted Delivery, Large Organization, Europe • Surgical Oncologist, Cancer Research Organization, Denver, North America • Doctor of Medicine, Cancer Research Organization, US, North America • Chief Executive Officer, Large Organization, UK, Europe NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation drug conjugates market, focusing on key market segments, including [A] type of drug conjugate, [B] type of targeting ligand, [C] type of payload, [D] route of administration, [E] type of therapy, [F] therapeutic area, [G] geographical regions, and [H] sales forecast. • Market Landscape: A detailed assessment of the overall next generation drug conjugates drugs landscape, featuring information on several relevant parameters, such as [A] stage of development, [B] type of conjugate, [C] mechanism of action, [D] type of therapy, [E] route of administration, [F] target indication, [G] therapeutic area, [H] target patient population [I] year of establishment, [J] company size, [K] location of headquarters, and [L] most active players. • Company Profiles: In-depth profiles of key drug developers in the next generation drug conjugate market, focusing on [A] company overview, [B] financial information, [C] drug portfolio, [D] recent developments and [E] an informed future outlook. • Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to next generation drug conjugates, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial phase, [D] trial status, [E] type of sponsor / collaborator, [F] patient gender, [G] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [H] leading industry and non-industry players (based on number of clinical trials) and [I] geography. • Partnerships and Collaborations: An analysis of partnerships and collaborations signed in the next generation drug conjugates market, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] therapeutic area, [D] most active players, and [E] regional analysis. • Academic Grants Analysis: A comprehensive academic grants analysis, based on several parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant and [G] most popular recipient organizations. • Publication Analysis: An insightful publication analysis, based on several parameters, such as [A] year of publication, [B] type of publication, [C] most active publishers, and [D] most popular journals. • Drug Failure Analysis: An insightful drug failure analysis, based on several parameters, such as [A] trial phase, [B] trial status, [C] reason for drug discontinuation, [D] study start year, [E] year of discontinuation, [F] type of molecule, and [G] route of administration. • Success Protocol Analysis: An insightful analysis of recently approved next generation drug conjugates, based on several relevant parameters, such as [A] dosing frequency, [B] drug exclusivity, [C] safety and efficacy, [D] geographical reach, [E] intra-class competition, [F] line of treatment, [G] prevalence, [H] price, [I] type of therapy, and [J] existing competition among developers. KEY QUESTIONS ANSWERED IN THIS REPORT • Which are the leading companies in the next generation drugs market? • Which region dominates the next generation drugs market? • What are the key trends observed in the next generation drugs market? • What factors are likely to influence the evolution of this market? • What are the primary challenges faced by next generation drug developers? • What is the current and future market size? • What is the CAGR of this market? • How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing. • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively. • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies. • The report allows for more effective communication with the audience and in building strong business relations. ADDITIONAL BENEFITS • Complementary Excel Data Packs for all Analytical Modules in the Report • 15% Free Content Customization • Detailed Report Walkthrough Session with Research Team • Free Updated report if the report is 6-12 months old or older

目錄 Table of Contents

1. BACKGROUND 1.1. Context 1.2. Project Objectives 2. RESEARCH METHODOLOGY 2.1. Chapter Overview 2.2. Research Assumptions 2.3. Database Building 2.4. Project Methodology 2.5. Robust Quality Control 3. MARKET DYNAMICS 3.1. Chapter Overview 3.2. Forecast Methodology 3.3. Market Assessment Framework 3.4. Forecasting Tools and Techniques 3.5. Key Considerations 3.6. Limitations 4. MACRO-ECONOMIC INDICATORS 4.1. Chapter Overview 4.2. Market Dynamics 4.2.3. Foreign Currency Exchange Rate 4.2.4. Recession 4.2.5. Inflation 4.2.6. Interest Rates 4.2.7. Commodity Flow Analysis 4.2.8. Global Trade Dynamics 4.2.9. War Impact Analysis 4.2.10. COVID Impact / Related Factors 4.2.11. Other Indicators 4.3. Conclusion 5. EXECUTIVE SUMMARY 5.1. Executive Summary: Market Landscape 5.2. Executive Summary: Market Trends 5.3. Executive Summary: Market Forecast and Opportunity Analysis 6. INTRODUCTION 6.1. Chapter Overview 6.2. Overview of Next Generation Drug Conjugates 6.3. Key Historical Events 6.4. Structure of Next Generation Drug Conjugates 6.5. Biochemical Interaction and Mechanism of Action 6.6. Key Target Indications 6.7. Advantages of Next Generation Drug Conjugates 6.8. Challenges Associated with Next Generation Drug Conjugates 6.9. Future Perspective 7. MARKET LANDSCAPE 7.1. Methodology and Key Parameters 7.2. Next Generation Drug Conjugates: List of Therapy Programs 7.2.1. Analysis by Stage of Development 7.2.2. Analysis by Type of Conjugate 7.2.3. Analysis by Mechanism of Action 7.2.4. Analysis by Type of Therapy 7.2.5. Analysis by Route of Administration 7.2.6. Analysis by Target Indication 7.2.7. Analysis by Therapeutic Area 7.2.8. Analysis by Target Patient Population 7.3. Next Generation Drug Conjugates Therapy Programs: Developer Landscape 7.3.1. Analysis by Year of Establishment 7.3.2. Analysis by Company Size 7.3.3. Analysis by Location of Headquarters 7.3.4. Most Active Players: Analysis by Number of Next Generation Drug Conjugates 8. COMPANY PROFILES 8.1. Alnylam Pharmaceuticals 8.1.1. Company Overview 8.1.2. Management Team 8.1.3. Drug Portfolio 8.1.4. Key Initiatives 8.2. Arrowhead Pharmaceuticals 8.3. Geron 8.4. Ionis Pharmaceuticals 8.5. Novartis 8.6. Novo Nordisk 8.7. Stemline Therapeutics 8.8. Telix Pharmaceuticals 9. CLINICAL TRIAL ANALYSIS 10. PARTNERSHIPS AND COLLABORATIONS 11. ACADEMIC GRANTS ANALYSIS 12. PUBLICATION ANALYSIS 13. DRUG FAILURE ANALYSIS 14. SUCCESS PROTOCOL ANALYSIS 15. GLOBAL NEXT GENERATION DRUG CONJUGATES MARKET 15.1. Chapter Overview 15.2. Key Assumptions and Methodology 15.3. Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 15.3.1. Scenario Analysis 15.3.1.1. Conservative Scenario 15.3.1.2. Optimistic Scenario 15.4. Key Market Segmentations 16. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF CONJUGATE 16.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate 16.1.1. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 16.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 16.1.3. Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 16.1.4. Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 16.1.5. Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 16.1.6. Next Generation Drug Conjugates Market for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 17. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF TARGETING LIGAND 17.1. Next Generation Drug Conjugates Market: Distribution by Type of Targeting Ligand 17.1.1. Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 17.1.2. Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 17.1.3. Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 17.1.4. Next Generation Drug Conjugates Market for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 17.1.5. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 18. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF PAYLOAD 18.1. Next Generation Drug Conjugates Market: Distribution by Type of Payload 18.1.1. Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 18.1.2. Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 18.1.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 18.1.4. Next Generation Drug Conjugates Market for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 18.1.5. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 19. NEXT GENERATION DRUG CONJUGATES MARKET, BY ROUTE OF ADMINISTRATION 19.1. Next Generation Drug Conjugates Market: Distribution by Route of Administration 19.1.1. Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 19.1.2. Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 19.1.3. Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 19.1.4. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 20. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF THERAPY 20.1. Next Generation Drug Conjugates Market: Distribution by Type of Therapy 20.1.1. Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 20.1.2. Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 20.1.3. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21. NEXT GENERATION DRUG CONJUGATES MARKET, BY THERAPEUTIC AREA 21.1. Next Generation Drug Conjugates Market: Distribution by Therapeutic Area 21.1.1. Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.2. Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.3. Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.4. Next Generation Drug Conjugates Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.5. Next Generation Drug Conjugates Market for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.6. Next Generation Drug Conjugates Market for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.7. Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 21.1.8. Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 22. NEXT GENERATION DRUG CONJUGATES MARKET, BY GEOGRAPHICAL REGIONS 23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA 23.1 Next Generation Drug Conjugates Market in North America: Distribution by Type of Conjugate 23.1.1. Next Generation Drug Conjugates Market in North America for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.1.2. Next Generation Drug Conjugates Market in North America for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.1.3. Next Generation Drug Conjugates Market in North America for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.1.4. Next Generation Drug Conjugates Market in North America for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.1.5. Next Generation Drug Conjugates Market in North America for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.1.6. Next Generation Drug Conjugates Market in North America for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.2. Next Generation Drug Conjugates Market in North America: Distribution by Type of Targeting Ligand 23.2.1. Next Generation Drug Conjugates Market in North America for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.2.2. Next Generation Drug Conjugates Market in North America for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.2.3. Next Generation Drug Conjugates Market in North America for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.2.4. Next Generation Drug Conjugates Market in North America for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.2.5. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.3. Next Generation Drug Conjugates Market in North America: Distribution by Type of Payload 23.3.1. Next Generation Drug Conjugates Market in North America for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.3.2. Next Generation Drug Conjugates Market in North America for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.3.3. Next Generation Drug Conjugates Market in North America for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.3.4. Next Generation Drug Conjugates Market in North America for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.3.5. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.4. Next Generation Drug Conjugates Market in North America: Distribution by Route of Administration 23.4.1. Next Generation Drug Conjugates Market in North America for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.4.2. Next Generation Drug Conjugates Market in North America for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.4.3. Next Generation Drug Conjugates Market in North America for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.4.4. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.5. Next Generation Drug Conjugates Market in North America: Distribution by Type of Therapy 23.5.1. Next Generation Drug Conjugates Market in North America for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.5.2. Next Generation Drug Conjugates Market in North America for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.5.3. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6. Next Generation Drug Conjugates Market in North America: Distribution by Therapeutic Area 23.6.1. Next Generation Drug Conjugates Market in North America for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.2. Next Generation Drug Conjugates Market in North America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.3. Next Generation Drug Conjugates Market in North America for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.4. Next Generation Drug Conjugates Market in North America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.5. Next Generation Drug Conjugates Market in North America for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.6. Next Generation Drug Conjugates Market in North America for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.7. Next Generation Drug Conjugates Market in North America for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 23.6.8. Next Generation Drug Conjugates Market in North America for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24. MARKET OPPORTUNITY ANALYSIS: EUROPE 24.1 Next Generation Drug Conjugates Market in Europe: Distribution by Type of Conjugate 24.1.1 Next Generation Drug Conjugates Market in Europe for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.1.2. Next Generation Drug Conjugates Market in Europe for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.1.3. Next Generation Drug Conjugates Market in Europe for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.1.4. Next Generation Drug Conjugates Market in Europe for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.1.5. Next Generation Drug Conjugates Market in Europe for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.1.6. Next Generation Drug Conjugates Market in Europe for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.2. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Targeting Ligand 24.2.1. Next Generation Drug Conjugates Market in Europe for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.2.2. Next Generation Drug Conjugates Market in Europe for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.2.3. Next Generation Drug Conjugates Market in Europe for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.2.4. Next Generation Drug Conjugates Market in Europe for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.2.5. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.3. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Payload 24.3.1. Next Generation Drug Conjugates Market in Europe for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.3.2. Next Generation Drug Conjugates Market in Europe for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.3.3. Next Generation Drug Conjugates Market in Europe for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.3.4. Next Generation Drug Conjugates Market in Europe for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.3.5. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.4. Next Generation Drug Conjugates Market in Europe: Distribution by Route of Administration 24.4.1. Next Generation Drug Conjugates Market in Europe for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.4.2. Next Generation Drug Conjugates Market in Europe for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.4.3. Next Generation Drug Conjugates Market in Europe for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.4.4. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.5. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Therapy 24.5.1. Next Generation Drug Conjugates Market in Europe for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.5.2. Next Generation Drug Conjugates Market in Europe for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.5.3. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6. Next Generation Drug Conjugates Market in Europe: Distribution by Therapeutic Area 24.6.1. Next Generation Drug Conjugates Market in Europe for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.2. Next Generation Drug Conjugates Market in Europe for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.3. Next Generation Drug Conjugates Market in Europe for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.4. Next Generation Drug Conjugates Market in Europe for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.5. Next Generation Drug Conjugates Market in Europe for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.6. Next Generation Drug Conjugates Market in Europe for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.7. Next Generation Drug Conjugates Market in Europe for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 24.6.8. Next Generation Drug Conjugates Market in Europe for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC 25.1 Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Conjugate 25.1.1. Next Generation Drug Conjugates Market in Asia-Pacific for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.1.2. Next Generation Drug Conjugates Market in Asia-Pacific for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.1.3. Next Generation Drug Conjugates Market in Asia-Pacific for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.1.4. Next Generation Drug Conjugates Market in Asia-Pacific for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.1.5. Next Generation Drug Conjugates Market in Asia-Pacific for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.1.6. Next Generation Drug Conjugates Market in Asia-Pacific for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.2. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Targeting Ligand 25.2.1. Next Generation Drug Conjugates Market in Asia-Pacific for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.2.2. Next Generation Drug Conjugates Market in Asia-Pacific for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.2.3. Next Generation Drug Conjugates Market in Asia-Pacific for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.2.4. Next Generation Drug Conjugates Market in Asia-Pacific for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.2.5. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.3. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Payload 25.3.1. Next Generation Drug Conjugates Market in Asia-Pacific for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.3.2. Next Generation Drug Conjugates Market in Asia-Pacific for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.3.3. Next Generation Drug Conjugates Market in Asia-Pacific for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.3.4. Next Generation Drug Conjugates Market in Asia-Pacific for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.3.5. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.4. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Route of Administration 25.4.1. Next Generation Drug Conjugates Market in Asia-Pacific for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.4.2. Next Generation Drug Conjugates Market in Asia-Pacific for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.4.3. Next Generation Drug Conjugates Market in Asia-Pacific for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.4.4. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.5. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Therapy 25.5.1. Next Generation Drug Conjugates Market in Asia-Pacific for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.5.2. Next Generation Drug Conjugates Market in Asia-Pacific for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.5.3. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Therapeutic Area 25.6.1. Next Generation Drug Conjugates Market in Asia-Pacific for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.2. Next Generation Drug Conjugates Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.3. Next Generation Drug Conjugates Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.4. Next Generation Drug Conjugates Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.5. Next Generation Drug Conjugates Market in Asia-Pacific for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.6. Next Generation Drug Conjugates Market in Asia-Pacific for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.7. Next Generation Drug Conjugates Market in Asia-Pacific for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 25.6.8. Next Generation Drug Conjugates Market in Asia-Pacific for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD 26.1 Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Conjugate 26.1.1. Next Generation Drug Conjugates Market in Rest of the World for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.1.2. Next Generation Drug Conjugates Market in Rest of the World for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.1.3. Next Generation Drug Conjugates Market in Rest of the World for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.1.4. Next Generation Drug Conjugates Market in Rest of the World for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.1.5. Next Generation Drug Conjugates Market in Rest of the World for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.1.6. Next Generation Drug Conjugates Market in Rest of the World for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.2. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Targeting Ligand 26.2.1. Next Generation Drug Conjugates Market in Rest of the World for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.2.2. Next Generation Drug Conjugates Market in Rest of the World for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.2.3. Next Generation Drug Conjugates Market in Rest of the World for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.2.4. Next Generation Drug Conjugates Market in Rest of the World for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.2.5. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.3. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Payload 26.3.1. Next Generation Drug Conjugates Market in Rest of the World for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.3.2. Next Generation Drug Conjugates Market in Rest of the World for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.3.3. Next Generation Drug Conjugates Market in Rest of the World for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.3.4. Next Generation Drug Conjugates Market in Rest of the World for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.3.5. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.4. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Route of Administration 26.4.1. Next Generation Drug Conjugates Market in Rest of the World for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.4.2. Next Generation Drug Conjugates Market in Rest of the World for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.4.3. Next Generation Drug Conjugates Market in Rest of the World for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.4.4. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.5. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Therapy 26.5.1. Next Generation Drug Conjugates Market in Rest of the World for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.5.2. Next Generation Drug Conjugates Market in Rest of the World for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.5.3. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Therapeutic Area 26.6.1. Next Generation Drug Conjugates Market in Rest of the World for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.2. Next Generation Drug Conjugates Market in Rest of the World for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.3. Next Generation Drug Conjugates Market in Rest of the World for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.4. Next Generation Drug Conjugates Market in Rest of the World for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.5. Next Generation Drug Conjugates Market in Rest of the World for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.6. Next Generation Drug Conjugates Market in Rest of the World for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.7. Next Generation Drug Conjugates Market in Rest of the World for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 26.6.8. Next Generation Drug Conjugates Market in Rest of the World for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) 27. NEXT GENERATION DRUG CONJUGATES MARKET: SALES FORECAST 27.1. AMVUTTRA® / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02: Sales Forecast (USD Million) 27.2. AAA617 / PLUVICTO: Sales Forecast (USD Million) 27.3. Leqvio® / inclisiran: Sales Forecast (USD Million) 27.4. ARO-APOC3 / Plozasiran / REDEMPLO: Sales Forecast (USD Million) 27.5. Imetelstat: Sales Forecast (USD Million) 27.6. Qfitlia™ / Fitusiran: Sales Forecast (USD Million) 27.7. TRYNGOLZA® / olezarsen: Sales Forecast (USD Million) 27.8. WAINZUA / Eplontersen: Sales Forecast (USD Million) 27.9. Illuccix® (68Ga-PSMA-11): Sales Forecast (USD Million) 27.10. AAA601 / Lutathera®: Sales Forecast (USD Million) 27.11. Gozellix®: Sales Forecast (USD Million) 27.12. DAWNZERA™ / donidalorsen: Sales Forecast (USD Million) 27.13. OXLUMO® / lumasiran: Sales Forecast (USD Million) 27.14. GIVLAARI® / givosiran: Sales Forecast (USD Million) 27.15. LNTH-2501 / EVG-001: Sales Forecast (USD Million) 27.16. Pelacarsen: Sales Forecast (USD Million) 27.17. Cemdisiran: Sales Forecast (USD Million) 27.18. SAR-bis PSMA: Sales Forecast (USD Million) 27.19. RYZ-101: Sales Forecast (USD Million) 27.20. ARO-ANG3 / Zodasiran: Sales Forecast (USD Million) 27.21. Bel-sar / AU-011: Sales Forecast (USD Million) 27.22. RBD7022 / QLC7401: Sales Forecast (USD Million) 28. CONCLUDING INSIGHTS 29. EXECUTIVE INSIGHTS 29.1. Chapter Overview 29.2. Company A 29.2.1. Company Snapshot 29.2.2. Interview Transcript: Doctor of Medicine, Large Company 29.3. Company B 29.3.1. Company Snapshot 29.3.2. Interview Transcript: Doctor of Medicine, Very Large Company 29.4. Company C 29.4.1. Company Snapshot 29.4.2. Interview Transcript: Vice President of Biologics Engineering and Tumor-Targeted Delivery, Large Company 29.5. Company D 29.5.1. Company Snapshot 29.5.2. Interview Transcript: Surgical Oncologist, Cancer Research Organization 29.6. Company E 29.6.1. Company Snapshot 29.6.2. Interview Transcript: Doctor of Medicine, Cancer Research Organization 29.7. Company F 29.7.1. Company Snapshot 29.7.2. Interview Transcript: Chief Executive Officer, Large Company 30. APPENDIX 1: TABULATED DATA 31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

圖表清單 List of Tables & Figures

Table 7.1 List of Next Generation Drug Conjugates Therapy Programs Table 7.2 List of Next Generation Drug Conjugate Developers Table 9.1 Next Generation Drug Conjugate Therapy Programs: List of Clinical Trials, (Since 2024) Table 10.1 Next Generation Drug Conjugates Market: List of Partnerships and Collaborations, (Since 2018) Table 11.1 Next Generation Drug Conjugates: List of Academic Grants, (Since 2018) Table 12.1 Next Generation Drug Conjugates Market: List of Publications, (Since 2020) Table 13.1 List of Discontinued Next Generation Drug Conjugates Table 15.1 Next Generation Drug Conjugates Market, Till 2035 Table 25.1 Next Generation Drug Conjugate Therapy Programs: Distribution by Stage of Development Table 25.2 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Conjugate Table 25.3 Next Generation Drug Conjugate Therapy Programs: Distribution by Mechanism of Action Table 25.4 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Therapy Table 25.5 Next Generation Drug Conjugate Therapy Programs: Distribution by Route of Administration Table 25.6 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Indication Table 25.7 Next Generation Drug Conjugate Therapy Programs: Distribution by Therapeutic Area Table 25.8 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Target Patient Population Table 25.9 Next Generation Drug Conjugate Developers: Distribution by Year of Establishment Table 25.10 Next Generation Drug Conjugate Developers: Distribution by Company Size Table 25.11 Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters Table 25.12 Next Generation Drug Conjugate Developers: Most Active Players: Distribution by Number of Next Generation Drug Conjugates Table 25.13 Clinical Trial Analysis: Analysis by Trial Registration Year (Since 2024) Table 25.14 Clinical Trial Analysis: Analysis by Trial Status Table 25.15 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status Table 25.16 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year Table 25.17 Clinical Trial Analysis: Analysis by Trial Phase Table 25.18 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase Table 25.19 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator Table 25.20 Clinical Trial Analysis: Analysis by Study Design Table 25.21 Clinical Trial Analysis: Analysis by Target Patient Population Table 25.22 Clinical Trial Analysis: Most Active Industry Players: Analysis by Number of Clinical Trials Table 25.23 Clinical Trial Analysis: Most Active Non-Industry Players: Analysis by Number of Clinical Trials Table 25.24 Clinical Trial Analysis: Analysis by Number of Clinical Trials and Patient Enrolled Table 25.25 Clinical Trial Analysis: Analysis by Number of Trials by Trial Status and Geography Table 25.26 Clinical Trial Analysis: Analysis by Trial Status and Geography Table 25.27 Clinical Trial Analysis: Analysis of Number of Patients Enrolled by Trial Status and Geography Table 25.28 Partnerships and Collaborations: Analysis by Year of Partnership Table 25.29 Partnerships and Collaborations: Analysis by Type of Partnership Table 25.30 Partnerships and Collaborations: Analysis by Year and Type of Partnership Table 25.31 Partnerships and Collaborations: Analysis by Therapeutic Area Table 25.32 Partnerships and Collaborations: Most Active Players: Analysis by Number of Partnerships Table 25.33 Partnerships and Collaborations: Analysis by Local and International Agreements Table 25.34 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements Table 25.35 Academic Grants Analysis: Analysis by Year of Grant Award Table 25.36 Academic Grants Analysis: Analysis by Amount Awarded (USD Million) Table 25.37 Academic Grants Analysis: Analysis by Funding Institute Center Table 25.38 Academic Grants Analysis: Analysis by Support Period Table 25.39 Academic Grants Analysis: Funding Institute Center and Support Period Table 25.40 Academic Grants Analysis: Analysis by Type of Grant Application Table 25.41 Academic Grants Analysis: Analysis by Purpose of Grant Table 25.42 Academic Grants Analysis: Analysis by Activity Code Table 25.43 Academic Grants Analysis: Analysis by Study Section Table 25.44 Academic Grants Analysis: Most Popular NIH Departments: Analysis by Number of Grants Table 25.45 Academic Grants Analysis: Type of Recipient Organization Table 25.46 Academic Grants Analysis: Popular Recipient Organizations: Analysis by Number of Grants Table 25.47 Academic Grants Analysis: Popular Recipient Organizations: Analysis by Amount Awarded (USD Million) Table 25.48 Academic Grants Analysis: Prominent Program Officers: Analysis by Number of Grants Table 25.49 Academic Grants Analysis: Prominent Program Officers: Location of Recipient Organizations in the US Table 25.50 Publication Analysis: Analysis by Year of Publication, Since 2020 Table 25.51 Publication Analysis: Analysis by Type of Publication Table 25.52 Publication Analysis: Analysis by Year and Type of Publication, Since 2020 Table 25.53 Most Active Publishers: Analysis by Number of Publications Table 25.54 Most Popular Journals: Analysis by Number of Publications Table 25.55 Most Popular Journals: Analysis by Impact Factor Table 25.56 Drug Failure Analysis: Analysis by Trial Phase Table 25.57 Drug Failure Analysis: Analysis by Trial Status Table 25.58 Drug Failure Analysis: Analysis by Reason for Drug Discontinuation Table 25.59 Drug Failure Analysis: Analysis by Study Start Year and Year of Discontinuation Table 25.60 Drug Failure Analysis: Analysis by Target Indication Table 25.61 Drug Failure Analysis: Analysis by Type of Conjugate Table 25.62 Drug Failure Analysis: Analysis by Type of Sponsor / Collaborator Table 25.63 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Scenario Analysis Table 25.64 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative Scenario Table 25.65 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Optimistic Scenario Table 25.66 Global Next Generation Drug Conjugates Market, Analysis by Type of Conjugate Table 25.67 Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.68 Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.69 Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.70 Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.71 Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Forecasted Estimates (Till 2035) Table 25.72 Next Generation Drug Conjugates Market for Radioconjugates Forecasted Estimates (Till 2035) Table 25.73 Global Next Generation Drug Conjugates Market, Analysis by Type of Targeting Ligand Table 25.74 Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.75 Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.76 Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.77 Next Generation Drug Conjugates Market for Virus-like Particles, Forecasted Estimates (Till 2035) Table 25.78 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2035) Table 25.79 Global Next Generation Drug Conjugates Market, Analysis by Type of Payload Table 25.80 Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.81 Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.82 Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.83 Next Generation Drug Conjugates Market for Drugs, Forecasted Estimates (Till 2035) Table 25.84 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2035) Table 25.85 Global Next Generation Drug Conjugates Market, Analysis by Route of Administration Table 25.86 Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.87 Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.88 Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.89 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.90 Global Next Generation Drug Conjugates Market, Analysis by Type of Therapy Table 25.91 Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2535) Table 25.92 Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2535) Table 25.93 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2535) Table 25.94 Global Next Generation Drug Conjugates Market, Analysis by Therapeutic Area Table 25.95 Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.96 Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.97 Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.98 Next Generation Drug Conjugates Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035) Table 25.99 Next Generation Drug Conjugates Market for Autoimmune Disorders, Forecasted Estimates (Till 2035) Table 25.100 Next Generation Drug Conjugates Market for Hematological Disorders, Forecasted Estimates (Till 2035) Table 25.101 Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.102 Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.103 Global Next Generation Drug Conjugates Market, Analysis by Geographical Regions Table 25.104 Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.105 Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.106 Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.107 Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.108 Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.109 Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.110 Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.111 Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.112 Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.113 Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.114 Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.115 Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.116 Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.117 Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.118 Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.119 Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.120 Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.121 Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.122 Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Table 25.123 Next Generation Drug Conjugate Market for AMVUTTRA® / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.124 Next Generation Drug Conjugates Market for AAA617 / PLUVICTO, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.125 Next Generation Drug Conjugates Market for Leqvio® / inclisiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.126 Next Generation Drug Conjugates Market for ARO-APOC3 / Plozasiran / REDEMPLO, Forecasted Estimates (Till 2035) (USD Million) Table 25.127 Next Generation Drug Conjugates Market for Imetelstat, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.128 Next Generation Drug Conjugates Market for Qfitlia™ / Fitusiran, Forecasted Estimates (Till 2035) (USD Million) Table 25.129 Next Generation Drug Conjugates Market for TRYNGOLZA® / olezarsen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.130 Next Generation Drug Conjugates Market for WAINZUA / Eplontersen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.131 Next Generation Drug Conjugates Market for Illuccix® (68Ga-PSMA-11), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.132 Next Generation Drug Conjugates Market for AAA601 / Lutathera®, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.133 Next Generation Drug Conjugates Market for Gozellix®, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.134 Next Generation Drug Conjugates Market for DAWNZERA™ / donidalorsen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.135 Next Generation Drug Conjugates Market for OXLUMO® / lumasiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.136 Next Generation Drug Conjugates Market for GIVLAARI® / givosiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million) Table 25.137 Next Generation Drug Conjugates Market for LNTH-2501 / EVG-001, Forecasted Estimates (Till 2035) (USD Million) Table 25.138 Next Generation Drug Conjugates Market for Pelacarsen, Forecasted Estimates (Till 2035) (USD Million) Table 25.139 Next Generation Drug Conjugates Market for Cemdisiran, Forecasted Estimates (Till 2035) (USD Million) Table 25.140 Next Generation Drug Conjugates Market for SAR-bis PSMA, Forecasted Estimates (Till 2035) (USD Million) Table 25.141 Next Generation Drug Conjugates Market for RYZ-101, Forecasted Estimates (Till 2035) (USD Million) Table 25.142 Next Generation Drug Conjugates Market for ARO-ANG3 / Zodasiran, Forecasted Estimates (Till 2035) (USD Million) Table 25.143 Next Generation Drug Conjugates Market for Bel-sar / AU-011, Forecasted Estimates (Till 2035) (USD Million) Table 25.144 Next Generation Drug Conjugates Market for RBD7022 / QLC7401, Forecasted Estimates (Till 2035) (USD Million) Figure 2.1 Research Methodology: Project Methodology Figure 2.2 Research Methodology: Data Sources for Secondary Research Figure 2.3 Research Methodology: Robust Quality Control Figure 3.1 Market Dynamics: Forecast Methodology Figure 3.2 Market Dynamics: Market Assessment Framework Figure 3.3 Market Dynamics: Example List of Parameters Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt Figure 5.1 Executive Summary: Market Landscape Figure 5.2 Executive Summary: Market Trends Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis Figure 6.1 Structure of Next Generation Drug Conjugates Figure 6.2 Biochemical Interaction and Mechanism of Action Figure 7.1 Next Generation Drug Conjugate Therapy Programs: Distribution by Stage of Development Figure 7.2 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Conjugate Figure 7.3 Next Generation Drug Conjugate Therapy Programs: Distribution by Mechanism of Action Figure 7.4 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Therapy Figure 7.5 Next Generation Drug Conjugate Therapy Programs: Distribution by Route of Administration Figure 7.6 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Indication Figure 7.7 Next Generation Drug Conjugate Therapy Programs: Distribution by Therapeutic Area Figure 7.8 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Patient Population Figure 7.9 Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters Figure 7.10 Next Generation Drug Conjugate Developers: Distribution by Year of Establishment Figure 7.11 Next Generation Drug Conjugate Developers: Distribution by Company Size Figure 7.12 Most Active Players: Distribution by Number of Next Generation Drug Conjugates Figure 9.1 Clinical Trial Analysis: Analysis by Trial Registration Year Figure 9.2 Clinical Trial Analysis: Analysis by Trial Status Figure 9.3 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status Figure 9.4 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year Figure 9.5 Clinical Trial Analysis: Analysis by Trial Phase Figure 9.6 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase Figure 9.7 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator Figure 9.8 Clinical Trial Analysis: Analysis by Study Design Figure 9.9 Clinical Trial Analysis: Analysis by Target Patient Population Figure 9.10 Most Active Industry Players: Analysis by Number of Clinical Trials Figure 9.11 Most Active Non- Industry Players: Analysis by Number of Clinical Trials Figure 9.12 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled Figure 9.13 Clinical Trial Analysis: Analysis by Trial Status and Geography Figure 9.14 Clinical Trial Analysis: Analysis of Patients Enrolled by Trial Status and Geography Figure 10.1 Partnerships and Collaborations: Analysis by Year of Partnership Figure 10.2 Partnerships and Collaborations: Analysis by Type of Partnership Figure 10.3 Partnerships and Collaborations: Analysis by Year and Type of Partnership Figure 10.4 Partnerships and Collaborations: Analysis by Therapeutic Area Figure 10.5 Most Active Players: Analysis by Number of Partnerships Figure 10.6 Partnerships and Collaborations: Analysis by Local and International Agreements Figure 10.7 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements Figure 11.1 Academic Grants Analysis: Analysis by Year of Grant Award Figure 11.2 Academic Grants Analysis: Analysis by Amount Awarded Figure 11.3 Academic Grants Analysis: Analysis by Funding Institute Center Figure 11.4 Academic Grants Analysis: Analysis by Support Period Figure 11.5 Academic Grants Analysis: Analysis by Funding Institute Center and Support Period Figure 11.6 Academic Grants Analysis: Analysis by Type of Grant Application Figure 11.7 Academic Grants Analysis: Analysis by Purpose of Grant Figure 11.8 Academic Grants Analysis: Analysis by Activity Code Figure 11.9 Academic Grants Analysis: Analysis by Study Section Figure 11.10 Popular NIH Departments: Analysis by Number of Grants Figure 11.11 Academic Grants Analysis: Analysis by Type of Recipient Organization Figure 11.12 Popular Recipient Organizations: Analysis by Number of Grants Figure 11.13 Popular Recipient Organizations: Analysis by Amount Awarded (USD Million) Figure 11.14 Prominent Program Officers: Analysis by Number of Grants Figure 11.15 Academic Grants Analysis: Analysis by Location of Recipient Organization in the US Figure 12.1 Publication Analysis: Analysis by Year of Publication Figure 12.2 Publication Analysis: Analysis by Type of Publication Figure 12.3 Publication Analysis: Analysis by Year and Type of Publication Figure 12.4 Most Active Publishers: Analysis by Number of Publications Figure 12.5 Most Popular Journals: Analysis by Number of Publications Figure 12.6 Most Popular Journals: Analysis by Impact Factor Figure 13.1 Drug Failure Analysis: Analysis by Trial Phase Figure 13.2 Drug Failure Analysis: Analysis by Trial Status Figure 13.3 Drug Failure Analysis: Analysis by Reason for Drug Discontinuation Figure 13.4 Drug Failure Analysis: Analysis by Study Start Year and Year of Discontinuation Figure 13.5 Drug Failure Analysis: Analysis by Target Indication Figure 13.6 Drug Failure Analysis: Analysis by Type of Conjugate Figure 13.7 Drug Failure Analysis: Analysis by Type of Sponsor / Collaborator Figure 14.1 Success Protocol Analysis: Spider Web Analysis for Lutathera Figure 14.2 Success Protocol Analysis: Spider Web Analysis for Pluvicto Figure 14.3 Success Protocol Analysis: Spider Web Analysis for Givlaari Figure 14.4 Success Protocol Analysis: Spider Web Analysis for Oxlumo Figure 14.5 Success Protocol Analysis: Spider Web Analysis for Amvuttra Figure 14.6 Success Protocol Analysis: Spider Web Analysis for Leqvio Figure 14.7 Harvey Ball Analysis: Assessment of Approved Next Generation Drug Conjugates across Key Parameters Figure 15.1 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Scenario Analysis Figure 15.2 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative Scenario Figure 15.3 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Optimistic Scenario Figure 16.1 Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 16.2 Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 16.3 Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 16.4 Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 16.5 Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 16.6 Next Generation Drug Conjugates Market for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 17.1 Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 17.2 Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 17.3 Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 17.4 Next Generation Drug Conjugates Market for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 17.5 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 18.1 Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 18.2 Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 18.3 Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 18.4 Next Generation Drug Conjugates Market for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 18.5 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 19.1 Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 19.2 Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 19.3 Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 19.4 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 20.1 Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 20.2 Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 20.3 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.1 Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.2 Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.3 Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.4 Next Generation Drug Conjugates Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.5 Next Generation Drug Conjugates Market for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.6 Next Generation Drug Conjugates Market for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.7 Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 21.8 Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.1 Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.2 Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.3 Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.4 Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.5 Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.6 Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.7 Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.8 Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.9 Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.10 Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.11 Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.12 Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.13 Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.14 Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.15 Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.16 Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.17 Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.18 Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 22.19 Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) Figure 23.1 Next Generation Drug Conjugates Market: Sales Forecast for AMVUTTRA® / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02 (USD Million) Figure 23.2 Next Generation Drug Conjugates Market: Sales Forecast for AAA617 / PLUVICTO (USD Million) Figure 23.3 Next Generation Drug Conjugates Market: Sales Forecast for Leqvio® / inclisiran (USD Million) Figure 23.4 Next Generation Drug Conjugates Market: Sales Forecast for ARO-APOC3 / Plozasiran / REDEMPLO (USD Million) Figure 23.5 Next Generation Drug Conjugates Market: Sales Forecast for Imetelstat (USD Million) Figure 23.6 Next Generation Drug Conjugates Market: Sales Forecast for Qfitlia™ / Fitusiran (USD Million) Figure 23.7 Next Generation Drug Conjugates Market: Sales Forecast for TRYNGOLZA® / olezarsen (USD Million) Figure 23.8 Next Generation Drug Conjugates Market: Sales Forecast for WAINZUA / Eplontersen (USD Million) Figure 23.9 Next Generation Drug Conjugates Market: Sales Forecast for Illuccix® (68Ga-PSMA-11) (USD Million) Figure 23.10 Next Generation Drug Conjugates Market: Sales Forecast for AAA601 / Lutathera® (USD Million) Figure 23.11 Next Generation Drug Conjugates Market: Sales Forecast for Gozellix® (USD Million) Figure 23.12 Next Generation Drug Conjugates Market: Sales Forecast for DAWNZERA™ / donidalorsen (USD Million) Figure 23.13 Next Generation Drug Conjugates Market: Sales Forecast for OXLUMO® / lumasiran (USD Million) Figure 23.14 Next Generation Drug Conjugates Market: Sales Forecast for GIVLAARI® / givosiran (USD Million) Figure 23.15 Next Generation Drug Conjugates Market: Sales Forecast for LNTH-2501 / EVG-001 (USD Million) Figure 23.16 Next Generation Drug Conjugates Market: Sales Forecast for Pelacarsen (USD Million) Figure 23.17 Next Generation Drug Conjugates Market: Sales Forecast for Cemdisiran (USD Million) Figure 23.18 Next Generation Drug Conjugates Market: Sales Forecast for SAR-bis PSMA (USD Million) Figure 23.19 Next Generation Drug Conjugates Market: Sales Forecast for RYZ-101 (USD Million) Figure 23.20 Next Generation Drug Conjugates Market: Sales Forecast for ARO-ANG3 / Zodasiran (USD Million) Figure 23.21 Next Generation Drug Conjugates Market: Sales Forecast for Bel-sar / AU-011 (USD Million) Figure 23.22 Next Generation Drug Conjugates Market: Sales Forecast for RBD7022 / QLC7401 (USD Million)

提及公司

48Hour DiscoveryAblaze PharmaceuticalsAdvanced Accelerator ApplicationsAkcea TherapeuticsAktis OncologyAlexion PharmaceuticalsAlnylam PharmaceuticalsAngiochemAntios TherapeuticsAptamer SciencesArbutus BiopharmaArisGlobalAro BiotherapeuticsArrowhead PharmaceuticalsAstraZenecaAsymchemAura BiosciencesAvacta TherapeuticsAvidity BiosciencesBayerBicycle TherapeuticsBiosynthBoehringer IngelheimCAMP4 TherapeuticsCaptarioCardinal HealthCase Western Reserve UniversityCellectar BiosciencesCerveau TechnologiesChemPartner

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們